Search research articles
Contact Us
Filters
Showing results (21-30 of 124) with videos related to
Page
of 13
Sort By:
Cancer Treatment Reports
|
January 1, 1983
Phase I-II evaluation of acronine in patients with multiple myeloma
J H Scarffe, A R Beaumont, D Crowther
British Journal of Hospital Medicine
|
April 1, 1982
Bone marrow transplantation
C G Geary, D I Evans, J H Scarffe
BMJ (Clinical Research Ed.)
|
January 5, 2000
Lack of funding will inhibit evidence based commissioning of cancer treatments
J So, J H Scarffe, E Rous, et al.
Lancet (London, England)
|
March 5, 1977
Abnormal blood lymphocytes in non-Hodgkin's lymphoma
J V Garrett, R K Newton, J H Scarffe
Cancer Treatment Reports
|
January 1, 1983
Phase II trial of vindesine in advanced gastric cancer
J B Kenny, J H Scarffe, W V Maley
European Journal of Cancer & Clinical Oncology
|
March 1, 1983
Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma
H Anderson, J H Scarffe, R Swindell, et al.
BMJ (Clinical Research Ed.)
|
February 12, 1999
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold
R Foy, J So, E Rous, et al.
British Journal of Haematology
|
May 1, 1979
Abnormal peripheral blood lymphocytes and bone marrow infiltration in non-Hodgkin's lymphoma
J V Garrett, J H Scarffe, R K Newton
Behring Institute Mitteilungen
|
August 1, 1988
Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor
W P Steward, J H Scarffe, R Austin, et al.
International Journal of Cell Cloning
|
January 1, 1990
Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor
W P Steward, J H Scarffe, E Bonnem, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 124) with videos related to
Sort By:
Page
of 13
Cancer Treatment Reports
|
January 1, 1983
Phase I-II evaluation of acronine in patients with multiple myeloma
J H Scarffe, A R Beaumont, D Crowther
British Journal of Hospital Medicine
|
April 1, 1982
Bone marrow transplantation
C G Geary, D I Evans, J H Scarffe
BMJ (Clinical Research Ed.)
|
January 5, 2000
Lack of funding will inhibit evidence based commissioning of cancer treatments
J So, J H Scarffe, E Rous, et al.
Lancet (London, England)
|
March 5, 1977
Abnormal blood lymphocytes in non-Hodgkin's lymphoma
J V Garrett, R K Newton, J H Scarffe
Cancer Treatment Reports
|
January 1, 1983
Phase II trial of vindesine in advanced gastric cancer
J B Kenny, J H Scarffe, W V Maley
European Journal of Cancer & Clinical Oncology
|
March 1, 1983
Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma
H Anderson, J H Scarffe, R Swindell, et al.
BMJ (Clinical Research Ed.)
|
February 12, 1999
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold
R Foy, J So, E Rous, et al.
British Journal of Haematology
|
May 1, 1979
Abnormal peripheral blood lymphocytes and bone marrow infiltration in non-Hodgkin's lymphoma
J V Garrett, J H Scarffe, R K Newton
Behring Institute Mitteilungen
|
August 1, 1988
Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor
W P Steward, J H Scarffe, R Austin, et al.
International Journal of Cell Cloning
|
January 1, 1990
Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor
W P Steward, J H Scarffe, E Bonnem, et al.
Page
of 13